BioNTech plans to invest up to £1 billion over the next 10 years

BioNTech计划在未来10年内投资高达10亿英镑。

to broaden its research and development activities for innovative medicines in the United Kingdom (“UK”)

扩大其在英国（“UK”）的创新药物研发活动

The UK Government will give BioNTech a grant of up to £129 million payable over a period of 10 years to support BioNTech’s research and development activities in the UK, marking one of the largest grants of its kind in UK history for a pharmaceutical company

英国政府将向BioNTech提供高达1.29亿英镑的补助金，分期10年支付，以支持BioNTech在英国的研发活动，这标志着这是英国历史上制药公司获得的最大补助之一。

Grant agreement builds on existing multi-year collaboration with the UK Government aimed at benefiting patients by accelerating clinical trials for personalized mRNA immunotherapies and focuses on establishing two new Research and Development (“R&D”) centers and a UK headquarters in London, accommodating BioNTech’s artificial intelligence (“AI”) hub.

该拨款协议建立在与英国政府现有的多年合作基础上，旨在通过加速个性化mRNA免疫疗法的临床试验造福患者，并侧重于在伦敦设立两个新的研发（“R&D”）中心和一个英国总部，以容纳BioNTech的人工智能（“AI”）中心。

MAINZ, Germany, May 20, 2025

德国美因茨，2025年5月20日

--

--

BioNTech SE

BioNTech SE

(Nasdaq: BNTX, “BioNTech” or “the Company”) today announced that its subsidiary BioNTech UK Ltd. signed a grant agreement with the UK Government to broaden the Company’s R&D activities for innovative medicines in the UK. As part of the agreement, BioNTech is committed to investing up to £1 billion over the next 10 years.

（纳斯达克：BNTX，“BioNTech”或“公司”）今天宣布，其子公司BioNTech英国有限公司与英国政府签署了一项资助协议，以扩大公司在英国的创新药物研发活动。根据协议，BioNTech承诺在未来10年内投资高达10亿英镑。

The Company’s efforts will be supported by a grant of up to £129 million for a period of 10 years by the UK Government, which marks one of the largest grants of its kind in UK history for a pharmaceutical company. The grant is part of the UK Government’s mission to enhance its life sciences sector and support innovative companies with the aim to unlock progress in medical science.

英国政府将在10年内提供高达1.29亿英镑的资助，支持该公司的努力，这是英国历史上制药公司获得的最大规模的拨款之一。该笔拨款是英国政府增强其生命科学领域和发展创新型企业使命的一部分，旨在推动医学科学的进步。

.

。

The grant agreement builds on a multi-year collaboration with the UK Government, announced in

该赠款协议建立在与英国政府多年合作的基础上，于

January 2023

2023年1月

, and is focused on three strategic pillars: (1) accelerating clinical trials for product candidates of BioNTech’s oncology pipeline, (2) investments into expanding BioNTech’s R&D footprint in the UK as one of the Company’s key markets, and (3) research into certain areas including structural biology, regenerative medicine, and infectious disease vaccines..

，并专注于三个战略支柱：(1) 加速推进BioNTech肿瘤学管线中候选产品临床试验，(2) 投资扩大BioNTech在英国的研发足迹，作为公司的关键市场之一，(3) 开展包括结构生物学、再生医学和传染病疫苗等特定领域的研究。

BioNTech plans to use the grant to support its establishment of two new R&D centers, the first of which will be based in Cambridge and a second of which is currently being planned. The Cambridge R&D center will focus on genomics, oncology, structural biology, and regenerative medicine, with capacity for more than 90 highly skilled scientists, including BioNTech’s existing scientists and researchers working in the UK.

BioNTech计划利用这笔拨款支持其建立两个新的研发中心，其中一个将设在剑桥，另一个正在规划中。剑桥研发中心将专注于基因组学、肿瘤学、结构生物学和再生医学，可容纳90多名高技能科学家，包括BioNTech现有的科学家和在英国工作的研究人员。

In addition, BioNTech will strengthen its footprint by establishing its UK headquarters in London, which will bring together the Company’s London-based teams and create new jobs in global and regional supporting functions in the UK over the next 10 years. BioNTech’s London office will also accommodate the Company’s artificial intelligence (“AI”) hub led by its wholly owned subsidiary InstaDeep Ltd.

此外，BioNTech将通过在伦敦设立英国总部来加强其影响力，该总部将整合公司位于伦敦的团队，并在未来十年内为英国的全球及区域支持功能创造新的就业机会。BioNTech的伦敦办公室还将容纳其全资子公司InstaDeep Ltd.领导的人工智能（“AI”）中心。

(“InstaDeep”), a leading global technology company in the field of AI and machine learning. BioNTech’s AI Hub plays a vital role in the Company’s research capabilities helping to advance AI-powered medical research..

(“InstaDeep”)是一家在人工智能和机器学习领域处于领先地位的全球技术公司。BioNTech的AI中心在其研究能力中发挥着至关重要的作用，有助于推动基于人工智能的医学研究。

These efforts are part of BioNTech’s global strategy to advance research and development of innovative cancer immunotherapies aimed at bringing multiple cancer treatments to the market by 2030, if successfully developed and approved. As of today, several hundred patients have gained access to investigational mRNA-based cancer immunotherapies in the UK through the collaboration as part of BioNTech’s global clinical trial programs. BioNTech’s ambition is to become a fully integrated, global immunotherapy powerhouse with the potential to improve the standard of care with innovative oncology products and prophylactic vaccines against infectious diseases​..

这些努力是BioNTech全球战略的一部分，旨在推进创新癌症免疫疗法的研发，目标是在2030年前将多种癌症治疗方案推向市场（如果研发成功并获得批准）。截至目前，通过与BioNTech全球临床试验项目的合作，已有数百名患者在英国获得了基于mRNA的实验性癌症免疫疗法。BioNTech的愿景是成为一家完全整合的全球免疫疗法领军企业，通过创新的肿瘤学产品和针对传染病的预防性疫苗，提升医疗标准。

About BioNTech

关于BioNTech

Biopharmaceutical New Technologies (BioNTech) is a global next generation immunotherapy company pioneering novel investigative therapies for cancer and other serious diseases. BioNTech exploits a wide array of computational discovery and therapeutic modalities with the intent of rapid development of novel biopharmaceuticals.

生物制药新技术公司（BioNTech）是一家全球性的下一代免疫治疗公司，致力于开发针对癌症和其他严重疾病的新型研究性疗法。BioNTech 利用广泛的计算发现和治疗模式，旨在快速开发新型生物制药。

Its diversified portfolio of oncology product candidates aiming to address the full continuum of cancer includes mRNA cancer immunotherapies, next-generation immunomodulators and targeted therapies such as antibody-drug conjugates (ADCs) and innovative chimeric antigen receptor (CAR) T cell therapies.

其多样化的肿瘤学产品候选组合旨在应对癌症的整个连续过程，包括mRNA癌症免疫疗法、下一代免疫调节剂和靶向疗法，如抗体药物偶联物（ADC）和创新的嵌合抗原受体（CAR）T细胞疗法。

Based on its deep expertise in mRNA development and in-house manufacturing capabilities, BioNTech and its collaborators are researching and developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global and specialized pharmaceutical collaborators, including Duality Biologics, Fosun Pharma, Genentech, a member of the Roche Group, Genevant, Genmab, MediLink, OncoC4, Pfizer and Regeneron..

基于其在mRNA开发方面的深厚专业知识和内部生产能力，BioNTech及其合作伙伴正在研究和开发多种针对一系列传染病的mRNA疫苗候选药物，同时推进其多样化的肿瘤学管线。BioNTech已经与多家全球性和专业性制药合作伙伴建立了广泛的合作关系，包括Duality Biologics、复星医药、罗氏集团成员Genentech、Genevant、Genmab、MediLink、OncoC4、辉瑞和Regeneron。

For more information, please visit

欲了解更多信息，请访问

www.BioNTech.com

www.BioNTech.com

.

。

BioNTech Forward-Looking Statements

BioNTech前瞻性声明

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: BioNTech’s potential collaboration with the Government of the United Kingdom and its institutions and authorities with regards to the provision of cancer immunotherapies, infectious disease vaccines and the expansion of BioNTech’s footprint in the United Kingdom, including the aim to provide personalized cancer therapies; plans to invest in a UK R&D hub in Cambridge; BioNTech's ability to reach an agreement with potential collaboration partners in the United Kingdom; BioNTech’s ability to develop, evaluate and commercialize products and product candidates, including the timing to initiate clinical trials; BioNTech’s anticipated market opportunity and size for its product candidates; and the rate and degree of market acceptance of BioNTech’s investigational medicines, if approved.

本新闻稿包含1995年《私人证券诉讼改革法案》（经修订）所指的前瞻性声明，包括但不限于以下方面的声明：BioNTech与英国政府及其机构和当局在提供癌症免疫疗法、传染病疫苗以及扩大BioNTech在英国的业务范围方面的潜在合作，其中包括提供个性化癌症治疗的目标；计划投资剑桥的英国研发基地；BioNTech与英国潜在合作伙伴达成协议的能力；BioNTech开发、评估和商业化产品及候选产品的能力，包括启动临床试验的时间；BioNTech对其候选产品的预期市场机会和规模；以及BioNTech的试验药物如果获批后的市场接受率和程度。

In some cases, forward-looking statements can be identified by terminology such as “will,” “may,” “should,” “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words..

在某些情况下，前瞻性陈述可以通过术语来识别，例如“将”、“可能”、“应该”、“预期”、“打算”、“计划”、“目标”、“预见”、“相信”、“估计”、“预测”、“潜在”、“继续”，或这些术语的否定形式或其他类似的术语，尽管并非所有前瞻性陈述都包含这些词语。

The forward-looking statements in this press release are based on BioNTech’s current expectations and beliefs of future events and are neither promises nor guarantees. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond BioNTech’s control and which could cause actual results to differ materially and adversely from those expressed or implied by these forward-looking statements.

本新闻稿中的前瞻性陈述基于BioNTech当前对未来事件的预期和信念，这些陈述既不是承诺也不是保证。您不应过度依赖这些前瞻性陈述，因为它们涉及已知和未知的风险、不确定性以及其他因素，其中许多因素超出BioNTech的控制范围，并可能导致实际结果与这些前瞻性陈述中明示或暗示的结果存在重大且不利的差异。

These risks and uncertainties include, but are not limited to: the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with preclinical and clinical data, and including the possibility of unfavorable new preclinical, clinical or safety data and further analyses of existing preclinical, clinical or safety data; the nature of clinical data, which is subject to ongoing peer review, regulatory review and market interpretation; the ability to produce comparable clinical results in future clinical trials; the timing of and BioNTech’s ability to obtain and maintain regulatory approval for its product candidates; discussions with regulatory agencies regarding timing and requirements for additional clinical trials; BioNTech’s and its counterparties’ ability to manage and source necessary energy resources; the impact of tariffs and escalations in trade policy; BioNTech’s ability to identify research opportunities and discover and develop investigational medicines; the ability and willingness of BioNTech’s third-party collaborators to continue research and developme.

这些风险和不确定性包括但不限于：研发过程中固有的不确定性，包括达到预期临床终点的能力、临床试验的启动和/或完成日期、监管提交日期、监管批准日期和/或上市日期，以及与临床前和临床数据相关的风险，包括可能出现不利的新的临床前、临床或安全性数据，以及对现有临床前、临床或安全性数据的进一步分析；临床数据的性质，需接受持续的同行评审、监管审查和市场解读；在未来临床试验中产生可比临床结果的能力；BioNTech获得并维持对其候选产品监管批准的能力及时间安排；与监管机构就额外临床试验的时间和要求进行的讨论；BioNTech及其交易对手管理及获取必要能源资源的能力；关税及贸易政策升级的影响；BioNTech识别研究机会以及发现和开发研究性药物的能力；BioNTech第三方合作伙伴继续进行研究和开发的意愿及能力。

You should review the risks and uncertainties described under the heading “Risk Factors” in BioNTech’s Report on Form 6-K for the period ended March 31, 2025 and in subsequent filings made by BioNTech with the SEC, which are available on the SEC’s website at

您应当查阅 BioNTech 在截至 2025 年 3 月 31 日的 Form 6-K 报告中标题为“风险因素”下描述的风险和不确定性，以及 BioNTech 随后向 SEC 提交的文件，这些文件可在 SEC 的网站上找到。

www.sec.gov

www.sec.gov

. These forward-looking statements speak only as of the date hereof. Except as required by law, BioNTech disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise..

这些前瞻性声明仅截至本日期有效。除非法律要求，否则BioNTech不承担更新或修改本新闻稿中包含的任何前瞻性声明的责任或意图，无论是否出现新信息、未来发展或其他情况。

CONTACTS

联系人

Media Relations

媒体关系

Jasmina Alatovic

雅斯米娜·阿拉托维奇

Media@biontech.de

媒体@biontech.de

Investor Relations

投资者关系

Michael Horowicz

迈克尔·霍罗威茨

Investors@biontech.de

投资者@biontech.de